179 related articles for article (PubMed ID: 9789529)
1. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma.
Horowitz B; Lazo A; Grossberg H; Page G; Lippin A; Swan G
Vox Sang; 1998; 74 Suppl 1():203-6. PubMed ID: 9789529
[TBL] [Abstract][Full Text] [Related]
2. Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS.
Biesert L; Suhartono H
Vox Sang; 1998; 74 Suppl 1():207-12. PubMed ID: 9789530
[TBL] [Abstract][Full Text] [Related]
3. Solvent/detergent-treated plasma: a tale of 30 years of experience.
Liumbruno GM; Marano G; Grazzini G; Capuzzo E; Franchini M
Expert Rev Hematol; 2015 Jun; 8(3):367-74. PubMed ID: 25695198
[TBL] [Abstract][Full Text] [Related]
4. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during Orthotopic Liver Transplantation.
Freeman JW; Williamson LM; Llewelyn C; Fisher N; Allain JP; Bellamy M; Baglin TP; Klinc J; Ala FA; Smith N; Neuberger J; Wreghitt T
Vox Sang; 1998; 74 Suppl 1():225-9. PubMed ID: 9789533
[TBL] [Abstract][Full Text] [Related]
6. 'Premium' plasma: isn't 'regular' blood safe enough?
Consum Rep; 1999 Sep; 64(9):61-3. PubMed ID: 10848094
[No Abstract] [Full Text] [Related]
7. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
8. Virally inactivated fresh frozen plasma.
Williamson LM; Allain JP
Vox Sang; 1995; 69(3):159-65. PubMed ID: 8578727
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP).
de Jonge J; Groenland TH; Metselaar HJ; IJzermans JN; van Vliet HH; Visser L; Tilanus HW
Anesth Analg; 2002 May; 94(5):1127-31, table of contents. PubMed ID: 11973173
[TBL] [Abstract][Full Text] [Related]
10. [Possibilities of virus inactivation of pooled fresh plasma with tri-n-butylphosphate (TNBP) detergents (SD procedure)].
Gürtler L
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():77-9. PubMed ID: 8000260
[TBL] [Abstract][Full Text] [Related]
11. Virus inactivation of fresh plasma.
Mohr H
Vox Sang; 1998; 74 Suppl 2():171-2. PubMed ID: 9704442
[No Abstract] [Full Text] [Related]
12. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses.
Hilfenhaus J; Gröner A; Nowak T; Weimer T
Transfusion; 1997 Sep; 37(9):935-40. PubMed ID: 9308641
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
14. Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate.
Roberts PL; Dunkerley C
Vox Sang; 2003 Apr; 84(3):170-5. PubMed ID: 12670365
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.
Williamson LM; Llewelyn CA; Fisher NC; Allain JP; Bellamy MC; Baglin TP; Freeman J; Klinck JR; Ala FA; Smith N; Neuberger J; Wreghitt TG
Transfusion; 1999; 39(11-12):1227-34. PubMed ID: 10604250
[TBL] [Abstract][Full Text] [Related]
16. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply.
AuBuchon JP; Birkmeyer JD
JAMA; 1994 Oct; 272(15):1210-4. PubMed ID: 7933351
[TBL] [Abstract][Full Text] [Related]
17. Viral safety of solvent/detergent-treated blood products.
Horowitz B; Prince AM; Hamman J; Watklevicz C
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S21-8; discussion S29-S30. PubMed ID: 7749045
[TBL] [Abstract][Full Text] [Related]
18. SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available.
Horowitz MS; Pehta JC
Vox Sang; 1998; 74 Suppl 1():231-5. PubMed ID: 9789534
[TBL] [Abstract][Full Text] [Related]
19. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.
Dichtelmüller HO; Biesert L; Fabbrizzi F; Gajardo R; Gröner A; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Pifat D; Osheroff W; Poelsler G
Transfusion; 2009 Sep; 49(9):1931-43. PubMed ID: 19497061
[TBL] [Abstract][Full Text] [Related]
20. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma.
Horowitz B; Bonomo R; Prince AM; Chin SN; Brotman B; Shulman RW
Blood; 1992 Feb; 79(3):826-31. PubMed ID: 1310064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
